Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a co-packaged therapeutic kit containing a combination of **Esomeprazole** (a proton pump inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is specifically designed as a 7-day or 14-day regimen for the eradication of *Helicobacter pylori*.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease to reduce the risk of ulcer recurrence.
## Adult Dosing
The standard regimen consists of:
* **Esomeprazole:** 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Duration:** Administered for 7 to 14 days, depending on local resistance patterns and clinical protocols.
## Pediatric Dosing
**Not established.** Sompraz HP is not indicated for use in pediatric patients. Safety and efficacy in children have not been determined.
## Dose Adjustments
* **Renal Impairment:** No specific adjustment for esomeprazole. Significant dose reduction or avoidance of Clarithromycin may be required in patients with severe renal impairment (CrCl <30 mL/min).
* **Hepatic Impairment:** Use caution with Clarithromycin and Esomeprazole in severe hepatic impairment.
* **Elderly:** No routine adjustment needed, but monitor for increased sensitivity to cardiac effects of Clarithromycin.
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any other macrolide or beta-lactam antibiotics.
* Concomitant use with cisapride, pimozide, astemizole, or terfenadine (due to risk of QT prolongation/arrhythmias with clarithromycin).
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, dysgeusia (bitter/metallic taste), nausea, abdominal pain, and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis), QT interval prolongation, and acute interstitial nephritis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent inhibitor of CYP3A4 and significantly increases levels of drugs like colchicine (fatal in renal/hepatic failure), statins, benzodiazepines, and oral anticoagulants (monitor INR).
* **pH-Dependent Absorption:** Esomeprazole may decrease the absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts).
* **Methotrexate:** PPIs may increase methotrexate levels.
## Monitoring
* **Efficacy:** Monitor for resolution of dyspeptic symptoms. Consider urea breath test or stool antigen test 4 weeks after therapy to confirm *H. pylori* eradication.
* **Safety:** Monitor for signs of *C. difficile* diarrhea and allergic reactions. Monitor ECG if patient is at risk for QT prolongation.
## Clinical Pearls
* **Adherence:** Patients must complete the full course to prevent antibiotic resistance.
* **Administration:** Esomeprazole should be taken at least 60 minutes before meals.
* **Allergies:** Always screen for penicillin allergies before initiating amoxicillin.
* **Taste:** The metallic taste from clarithromycin is a common cause of non-adherence; patients should be counseled that this is expected.
***
**Disclaimer:** This information is for educational purposes only. Always verify dosing, contraindications, and drug interactions against current institutional protocols, local resistance patterns, and the most recent manufacturer prescribing information (package insert) before clinical decision-making.
